Two of Heparin Therapeutics’ founders, Professor Frank M.P. van Haren and Professor Clive Page, served as lead and co-author on the peer-reviewed paper, which reported results from a prospective, multicenter, international collaborative meta-trial of six randomized clinical studies. These important results were also presented by Professor van Haren at the European Respiratory Society Congress on 28th September 2025.

In this meta-trial, hospitalized but non-intubated COVID-19 patients were randomly assigned to receive inhaled, nebulized unfractionated heparin (UFH) plus standard of care, or standard of care alone. UFH significantly reduced intubation and reduced mortality. Treatment was safe, with no serious adverse effects, no pulmonary or major bleeding, and no impact on systemic coagulation.
“This important Heparin Therapeutics’ study highlights the potential of inhaled UFH as a safe and efficacious therapy, and has implications for the future treatment of lung injury arising from diseases such as COVID-19, ARDS and other respiratory conditions.” shared Bill Humphries, MedPharm CEO. “As their CDMO partner, MedPharm is proud to work alongside Heparin Therapeutics to develop a proprietary UFH product that will bring this innovation closer to patients, advancing an important new option in lung delivery.”

For further details, please see the full publication and press releases:

https://www.sciencedirect.com/science/article/pii/S2589537025002718

https://www.kcl.ac.uk/news/low-cost-drug-shows-promise-for-patients-with-life-threating-respiratory-infections

https://reporter.anu.edu.au/all-stories/low-cost-drug-shows-promise-for-patients-with-life-threatening-respiratory-infections

About MedPharm
MedPharm is an end-to-end contract service provider of topical and transepithelial products supporting early-phase research, formulation development and in vitro testing services in addition to both clinical and commercial manufacturing. With MedPharm’s merger with Tergus Pharma, MedPharm enhanced its capabilities, transforming the business into a truly differentiated CDMO of scale with superior end-to-end capabilities from drug development and formulation to large batch commercial manufacturing and distribution. For more than 25 years, MedPharm has specialized in reducing risk through its unique, industry-leading in vitro testing and research biology models and is a global leader in product development for dermal/transdermal, lung and nasal, mucosal membrane, ungual, otic, and ophthalmic delivery. MedPharm has locations in the United Kingdom and the United States, including a new 97,000 sq. ft. state-of-the-art manufacturing facility in Durham, NC. For more information, visit medpharm.com or follow us on LinkedIn.

About Heparin Therapeutics
Heparin Therapeutics’ team of world-class scientists and researchers specialize in the development and optimization of heparin-based therapies, pushing the boundaries of medical science to offer groundbreaking solutions for a range of medical conditions. With a focus on inhalation administration, we aim to develop safe and highly differentiated pulmonary treatments for acute and chronic respiratory diseases to that enhance patient comfort and compliance.

There is a significant unmet need for treatments aimed at reducing lung inflammation in both ICU and outpatient settings. Prolonged time on ventilators is associated with poor outcomes, underscoring the necessity for effective therapies. The efficacy and safety of Unfractionated Heparin in the treatment of respiratory disease has been demonstrated through more than 50 clinical studies involving our founders investigating the off-label nebulisation of commercially available of heparin injections in respiratory disease. However, despite the impressive clinical outcomes such an approach results in sub-optimal suboptimal lung delivery and retention and is impractical for routine clinical use and so currently, no approved inhaled UFH product exists.

Heparin Therapeutics is pioneering HT-231, the first patented, safe, and well- tolerated unfractionated heparin (UFH) nebulized medicine utilizing our proprietary drug delivery platform, for the treatment of Acute Respiratory Distress Syndrome (ARDS). This PoC data is expected to be translatable to other prevalent lung diseases including Chronic Obstructive Pulmonary disease (COPD), Asthma, Idiopathic Pulmonary Fibrosis (IPF) and Bronchiectasis. For more information, visit www.heparintherapeutics.com.